Activity of Cefiderocol and Comparators against Isolates from Cancer Patients | Zendy

Kenneth V. I. Rolston | Zendy; Baghat Gerges | Zendy; Samuel A. Shelburne | Zendy; Samuel L Aitken | Zendy; Issam Raad | Zendy; Randall A. Prince | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Activity of Cefiderocol and Comparators against Isolates from Cancer Patients

Author(s) -

Kenneth V. I. Rolston,

Baghat Gerges,

Samuel A. Shelburne,

Samuel L Aitken,

Issam Raad,

Randall A. Prince

Publication year - 2020

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01955-19

Subject(s) - cancer , biology , medicine , computational biology , genetics

Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at ≤4 mg/liter. It had potent activity against extended-spectrum β-lactamase-positive Enterobacteriaceae , carbapenem-resistant Enterobacteriaceae (CRE), and nonfermenting Gram-negative bacilli, including Pseudomonas aeruginosa , Stenotrophomonas maltophilia , and Acinetobacter species isolates. Amikacin, ceftazidime-avibactam, and meropenem had appreciable activity against non-CRE Enterobacteriaceae No comparators were active against multidrug-resistant P. aeruginosa isolates. Only trimethoprim-sulfamethoxazole had appreciable activity against S. maltophilia isolates. Overall, cefiderocol was associated with the lowest level of resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research